Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular mechanisms for tumour resistance to chemotherapy
Shuting Pan, Zhiling Li, Zhixu He, et al.
Clinical and Experimental Pharmacology and Physiology (2016) Vol. 43, Iss. 8, pp. 723-737
Open Access | Times Cited: 360

Showing 1-25 of 360 citing articles:

Drug resistance and combating drug resistance in cancer
Xuan Wang, Haiyun Zhang, Xiaozhuo Chen
Cancer Drug Resistance (2019)
Open Access | Times Cited: 871
Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment
Beatriz García-Pinel, Cristina Porras-Alcalá, Alicia Ortega-Rodríguez, et al.
Nanomaterials (2019) Vol. 9, Iss. 4, pp. 638-638
Open Access | Times Cited: 420
Adipocyte and lipid metabolism in cancer drug resistance
Yihai Cao
Journal of Clinical Investigation (2019) Vol. 129, Iss. 8, pp. 3006-3017
Open Access | Times Cited: 388
Nanotechnology for Cancer Therapy Based on Chemotherapy
Chenyang Zhao, Rui Cheng, Zhe Yang, et al.
Molecules (2018) Vol. 23, Iss. 4, pp. 826-826
Open Access | Times Cited: 291
Drug resistance in cancer: mechanisms and tackling strategies
Tanweer Haider, Vikas Pandey, Nagma Banjare, et al.
Pharmacological Reports (2020) Vol. 72, Iss. 5, pp. 1125-1151
Closed Access | Times Cited: 215
Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)
Hang Zhang, Hai‐Wei Xu, Charles R. Ashby, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 1, pp. 525-555
Closed Access | Times Cited: 206
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance
Jing‐Quan Wang, Yuqi Yang, Chao‐Yun Cai, et al.
Drug Resistance Updates (2021) Vol. 54, pp. 100743-100743
Closed Access | Times Cited: 177
Macrophage-mimic shape changeable nanomedicine retained in tumor for multimodal therapy of breast cancer
Rui Liu, Yang An, Wenfeng Jia, et al.
Journal of Controlled Release (2020) Vol. 321, pp. 589-601
Closed Access | Times Cited: 155
Therapeutic strategies to overcome taxane resistance in cancer
Tuyelee Das, Uttpal Anand, Swaroop Kumar Pandey, et al.
Drug Resistance Updates (2021) Vol. 55, pp. 100754-100754
Closed Access | Times Cited: 154
The Mechanism of Warburg Effect-Induced Chemoresistance in Cancer
Chang Liu, Ying Jin, Zhimin Fan
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 136
Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects
Sepideh Mirzaei, Mohammad Gholami, Farid Hashemi, et al.
Drug Discovery Today (2021) Vol. 27, Iss. 2, pp. 436-455
Open Access | Times Cited: 132
Targeting Drug Chemo-Resistance in Cancer Using Natural Products
Wamidh H. Talib, Ahmad R. Alsayed, Muna Barakat, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1353-1353
Open Access | Times Cited: 129
A Review of the Current Impact of Inhibitors of Apoptosis Proteins and Their Repression in Cancer
Pierina Cetraro, Julio Plaza‐Díaz, Alex MacKenzie, et al.
Cancers (2022) Vol. 14, Iss. 7, pp. 1671-1671
Open Access | Times Cited: 77
Beyond matrix stiffness: targeting force-induced cancer drug resistance
Maria Kalli, Matthew D. Poskus, Triantafyllos Stylianopoulos, et al.
Trends in cancer (2023) Vol. 9, Iss. 11, pp. 937-954
Open Access | Times Cited: 52
Overcoming Chemotherapy Resistance in Metastatic Cancer: A Comprehensive Review
Maryam Eslami, Omid Memarsadeghi, Ali Davarpanah, et al.
Biomedicines (2024) Vol. 12, Iss. 1, pp. 183-183
Open Access | Times Cited: 29
Schiff bases and their metal complexes to target and overcome (multidrug) resistance in cancer
Ana Podolski-Renić, Ana Čipak Gašparović, Andreia Valente, et al.
European Journal of Medicinal Chemistry (2024) Vol. 270, pp. 116363-116363
Closed Access | Times Cited: 23
Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy
Deepak Chandra Joshi, Anurag Sharma, Sonima Prasad, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 23
Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer
Yixiang Gu, Ruifeng Yang, Yang Zhang, et al.
Molecular Biomedicine (2025) Vol. 6, Iss. 1
Open Access | Times Cited: 5
In vitro and in vivo anticancer efficacy potential of Quercetin loaded polymeric nanoparticles
Ruma Baksi, Devendra Pratap Singh, Swapnil Borse, et al.
Biomedicine & Pharmacotherapy (2018) Vol. 106, pp. 1513-1526
Closed Access | Times Cited: 148
Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells
Dauren Alimbetov, Sholpan Askarova, Bauyrzhan Umbayev, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 6, pp. 1690-1690
Open Access | Times Cited: 135
Molecular Engineered Squaraine Nanoprobe for NIR-II/Photoacoustic Imaging and Photothermal Therapy of Metastatic Breast Cancer
Defan Yao, Yanshu Wang, Rongfeng Zou, et al.
ACS Applied Materials & Interfaces (2020) Vol. 12, Iss. 4, pp. 4276-4284
Closed Access | Times Cited: 130
Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
Meng Zhang, Ergang Liu, Yanna Cui, et al.
Cancer Biology and Medicine (2017) Vol. 14, Iss. 3, pp. 212-212
Open Access | Times Cited: 108
Betulinic acid chemosensitizes breast cancer by triggering ER stress-mediated apoptosis by directly targeting GRP78
Youli Cai, Yifeng Zheng, Jiangyong Gu, et al.
Cell Death and Disease (2018) Vol. 9, Iss. 6
Open Access | Times Cited: 106
Pathogenesis of Cholangiocarcinoma
Pedro M. Rodrigues, Paula Olaizola, Nuno A. Paiva, et al.
Annual Review of Pathology Mechanisms of Disease (2020) Vol. 16, Iss. 1, pp. 433-463
Open Access | Times Cited: 106
Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters
Ying-Fang Fan, Wei Zhang, Leli Zeng, et al.
Cancer Letters (2018) Vol. 421, pp. 186-198
Open Access | Times Cited: 103
Page 1 - Next Page

Scroll to top